Point72 Asset Management
CYCN icon

Point72 Asset Management’s Cyclerion Therapeutics CYCN Stock Holding History

Point72 Asset Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,961
Closed -$379K – 831
2019
Q4 		$379K Buy
+6,961
New +$650K ﹤0.01% 797

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Point72 Asset Management's CYCN Position: Q1 2020 in Review

Point72 Asset Management sold out of Cyclerion Therapeutics (CYCN) in Q1 2020, closing a stake of 6,961 shares — an estimated $379K sold.

Point72 Asset Management first reported a position in CYCN in Q4 2019 and held it in 1 quarter. The position peaked at $379K in Q4 2019. 80 funds tracked by Wall St. Rank hold CYCN as of Q1 2020.

  • Point72 Asset Management reported no remaining Cyclerion Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Point72 Asset Management sold 6,961 Cyclerion Therapeutics shares in Q1 2020, an estimated $379K.
  • Point72 Asset Management first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 1 quarter.
  • Point72 Asset Management's Cyclerion Therapeutics position peaked at $379K in Q4 2019.
  • 80 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2020.

Based on Point72 Asset Management's 13F filing for Q1 2020, filed 15 May 2020.